Health status decline in α-1 antitrypsin deficiency: A feasible outcome for disease modifying therapies?

Respiratory Research

Volumn 19, Issue 1, 2018, Pages

  Stockley, Robert A ^a   Edgar, Ross G ^b,c   Starkey, Sian ^b   Turner, Alice M ^b,c  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Alpha 1 antitrypsin deficiency; Disease progression; Health related quality of life

Indexed keywords

ADULT; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DETERIORATION; DISEASE ASSOCIATION; DISEASE COURSE; EFFECT SIZE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH STATUS; HUMAN; MALE; ST. GEORGE RESPIRATORY QUESTIONNAIRE; AGED; CROSS-SECTIONAL STUDY; DISEASE EXACERBATION; MIDDLE AGED; REGISTER; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA 1-ANTITRYPSIN DEFICIENCY; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGISTRIES; TREATMENT OUTCOME;

EID: 85050284592     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-018-0844-6     Document Type: Article

References (35)

1. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184-92.
2. Nishimura M, Makita H, Nagai K, Konno S, Nasuhara Y, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(1):44-52.
3. Park HY, Churg A, Wright JL, Li Y, Tam S, et al. Club cell protein 16 and disease progression in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188(12):1413-9.
4. Carter R, Mumford R, Treonze K, Stockley R. Fibrinopeptide AA-VAL360: a footprint of neutrophil elastase activity. COPD: J Chron Obstruct Pulmon Dis. 2011;8(1):50-1.
5. Dowson LJ, Guest PJ, Hill SL, Holder RL, Stockley RA. High-resolution computed tomography scanning in alpha1-antitrypsin deficiency: relationship to lung function and health status. Eur Respir J. 2001;17(6):1097-104.
6. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5):1418-22.
7. U.S. Food and Drug Administration. Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment Guidance for Industry (Draft Guidance). 2016 [Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071575.pdf.
8. U.S. Food and Drug Administration. In: U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER), editor. Chronic Obstructive Pulmonary Disease: Use of the St. George's Respiratory Questionnaire as a PRO Assessment Tool Guidance for Industry; 2018.
9. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178(4):332-8.
10. Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817-26.
11. Schluchter MD, Stoller JK, Barker AF, Buist AS, Crystal RG, et al. Feasibility of a clinical trial of augmentation therapy for alpha1- antitrypsin deficiency. Am J Respir Crit Care Med. 2000;161(3 I):796-801.
12. Plasma Protein Therapeutics Association. Clinical and Surrogate Endpoints for Evaluating Efficacy of Alpha 1-Proteinase Inhibitor (Human) Augmentation Therapy: FDA Blood Products Advisory Committee; 2009. [Available from: https://www.pptaglobal.org/./954-ppta-statement-on-clinical-and-surrogate-endpoints.
13. Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, et al. Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9991):360-8.
14. Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DCS, et al. A randomized clinical trial of alpha1-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999;160(5 I):1468-72.
15. Dirksen A, Piitulainen E, Parr DG, Deng C, Wencker M, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J. 2009;33(6):1345-53.
16. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. A J Respir Crit Care Med. 1998;158(1):49-59.
17. Dowson LJ, Newall C, Guest PJ, Hill SL, Stockley RA. Exercise capacity predicts health status in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2001;163(4):936-41.
18. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease 2017 report. Respirology. 2017;22(3):575-601.
19. Stockley RA, Edgar RG, Pillai A, Turner AM. Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management? Int J Chron Obstruct Pulmon Dis. 2016;11:1745.
20. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, et al. Lung volumes and forced ventilatory flows. Eur Respir J. 1993;6(Suppl 16):5-40.
21. Ward H, Turner AM, Stockley RA. Spirometric and gas transfer discordance in a alpha1 -antitrypsin deficiency. Patient characteristics and progression. Chest. 2014;145(6):1316-24.
22. Ferrer M, Villasante C, Alonso J, Sobradillo V, Gabriel R, et al. Interpretation of quality of life scores from the St George's respiratory questionnaire. Eur Respir J. 2002;19(3):405-13.
23. Piitulainen E, Mostafavi B, Tanash HA. Health status and lung function in the swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 years. Int J Chron Obstruct Pulmon Dis. 2017;12:495.
24. Needham M, Stockley RA. Exacerbations in alpha1-antitrypsin deficiency. Eur Respir J. 2005;25(6):992-1000.
25. Stolk J, Ng WH, Bakker ME, Reiber JHC, Rabe KF, et al. Correlation between annual change in health status and computer tomography derived lung density in subjects with alpha1-antitrypsin deficiency. Thorax. 2003;58(12):1027-30.
26. Bernhard N, Lepper PM, Vogelmeier C, Seibert M, Wagenpfeil S, et al. Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency-analysis from the german registry. Int J Chron Obstruct Pulmon Dis. 2017;12:1427.
27. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002;19(2):209-16.
28. Vestbo J, Anderson JA, Calverley PM, Celli B, Ferguson GT, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64(11):939-43.
29. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449-56.
30. Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;169(12):1298-303.
31. Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Libr. 2016; https://doi.org/10.1002/14651858.CD007851.pub3.
32. Linden A. Assessing regression to the mean effects in health care initiatives. BMC Med Res Methodol. 2013;13(1):119.
33. Stolk J, Cooper BG, Stoel B, Rames A, Rutman O, et al. Retinoid treatment of emphysema in patients on the Alpha-1 international registry. The REPAIR study: study design, methodology and quality control of study assessments. Ther Adv Respir Dis. 2010;4(6):319-32.
34. Dawkins P, Wood A, Nightingale P, Stockley R. Mortality in alpha-1-antitrypsin deficiency in the United Kingdom. Respir Med. 2009;103(10):1540-7.
35. Parr DG, Stoel BC, Stolk J, Stockley RA. Validation of computed tomographic lung densitometry for monitoring emphysema in alpha1-antitrypsin deficiency. Thorax. 2006;61(6):485-90.